Rapport Therapeutics Cash Flow Statement
NASDAQ: RAPPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
30.65+0.80 (+2.68%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rapport Therapeutics free cash flow
In fiscal 2025, Rapport Therapeutics generated -$87.5 million of operating cash flow and spent $616,000 on capital expenditures. That left free cash flow of -$88.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Rapport Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -111.48M | -78.31M | -34.79M |
| Net Income growth (YoY) | — | — | — |
| Depreciation & Amortization | 1.02M | 839.00K | 112.00K |
| Stock-Based Compensation | 18.86M | 10.23M | 3.52M |
| Change in Working Capital | 1.42M | -263.00K | 616.00K |
| Operating Cash Flow | -87.47M | -64.83M | -27.18M |
| Capital Expenditures | -616.00K | -2.40M | -1.64M |
| Investing Cash Flow | -187.47M | -170.14M | -78.86M |
| Financing Cash Flow | 270.79M | 221.63M | 145.14M |
| Net Change in Cash | -4.16M | -13.34M | 39.09M |
| Free Cash Flow | -88.09M | -67.23M | -28.82M |
This table shows 3 annual periods of Rapport Therapeutics's cash flow statement, from FY 2025 back to FY 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RAPP's reporting calendar. What is a cash flow statement?